Nancy Sullivan
#119,583
Most Influential Person Across History
American cell biologist
Nancy Sullivan 's AcademicInfluence.com Rankings
Download Badge
Biology
Why Is Nancy Sullivan Influential?
(Suggest an Edit or Addition)According to Wikipedia, Nancy Jean Sullivan is an American cell biologist researching filovirus immunology and vaccine development. She is a senior investigator and chief of the biodefense research section at the Vaccine Research Center. Her team discovered the monoclonal antibody, mAb114.
Nancy Sullivan 's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates (1996) (2485)
- Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 (1996) (1138)
- Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates (2020) (809)
- CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophage-tropic HIV-1, In Vitro (1997) (797)
- Endosomal Proteolysis of the Ebola Virus Glycoprotein Is Necessary for Infection (2005) (797)
- Development of a preventive vaccine for Ebola virus infection in primates (2000) (658)
- Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses (2005) (626)
- Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates (2003) (482)
- Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury (2000) (394)
- A Recombinant Vesicular Stomatitis Virus Ebola Vaccine (2017) (333)
- Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody (2016) (329)
- CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization (1998) (322)
- Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge (2014) (318)
- Two Orphan Seven-Transmembrane Segment Receptors Which Are Expressed in CD4-positive Cells Support Simian Immunodeficiency Virus Infection (1997) (315)
- Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates (1995) (314)
- A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. (2015) (295)
- Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine (2021) (286)
- SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters (2022) (267)
- Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein (1997) (251)
- Neutralizing Antibody Fails to Impact the Course of Ebola Virus Infection in Monkeys (2007) (233)
- Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions (1993) (233)
- A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial (2006) (229)
- A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. (2010) (202)
- SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination (2022) (202)
- Immune Protection of Nonhuman Primates against Ebola Virus with Single Low-Dose Adenovirus Vectors Encoding Modified GPs (2006) (200)
- CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates (2011) (199)
- Chimpanzee Adenovirus Vector Ebola Vaccine (2017) (192)
- Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial (2016) (190)
- Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge (2011) (190)
- Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule (2009) (186)
- Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates (2021) (176)
- Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody (1993) (175)
- Ebola Virus Pathogenesis: Implications for Vaccines and Therapies (2003) (167)
- Structural and molecular basis for Ebola virus neutralization by protective human antibodies (2016) (166)
- Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake (2017) (152)
- Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120 (1993) (149)
- Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Activation by Soluble CD4 and Monoclonal Antibodies (1998) (143)
- Immunopathology of highly virulent pathogens: insights from Ebola virus (2007) (135)
- Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. (2016) (133)
- Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants (2021) (133)
- Ebolavirus Proteins Suppress the Effects of Small Interfering RNA by Direct Interaction with the Mammalian RNA Interference Pathway (2011) (133)
- LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants (2021) (130)
- Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains (1993) (122)
- Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine - Preliminary Report. (2021) (119)
- Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species (2010) (117)
- Filoviruses Require Endosomal Cysteine Proteases for Entry but Exhibit Distinct Protease Preferences (2012) (108)
- Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial (2014) (107)
- Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. (1995) (106)
- Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial (2015) (103)
- mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron (2022) (98)
- Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp120 third variable region and gp41 amino terminus (1992) (97)
- Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. (1996) (94)
- Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic (2017) (91)
- Induction of dendritic spines by an extracellular domain of AMPA receptor subunit GluR 2 (90)
- Functional Interrogation and Mining of Natively-Paired Human VH:VL Antibody Repertoires (2017) (89)
- Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms (2010) (85)
- LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants (2022) (82)
- Ebola Virus Glycoprotein Toxicity Is Mediated by a Dynamin-Dependent Protein-Trafficking Pathway (2005) (81)
- Antibody-mediated enhancement of viral disease. (2001) (78)
- Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study (2019) (78)
- Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529 (2021) (77)
- Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule (2009) (77)
- Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA (2013) (71)
- Vector Choice Determines Immunogenicity and Potency of Genetic Vaccines against Angola Marburg Virus in Nonhuman Primates (2010) (66)
- mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron (2022) (65)
- Camouflage and Misdirection: The Full-On Assault of Ebola Virus Disease (2014) (64)
- Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor. (2006) (63)
- The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters (2021) (62)
- Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates (2021) (62)
- Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae (2013) (60)
- Yang, Z.-Y. et al. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 6, 886-889 (2000) (60)
- Defining the risk of SARS-CoV-2 variants on immune protection (2022) (58)
- Filovirus RefSeq Entries: Evaluation and Selection of Filovirus Type Variants, Type Sequences, and Names (2014) (53)
- A Platform Incorporating Trimeric Antigens into Self-Assembling Nanoparticles Reveals SARS-CoV-2-Spike Nanoparticles to Elicit Substantially Higher Neutralizing Responses than Spike Alone (2020) (48)
- Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates (2021) (47)
- Ebolavirus vaccines for humans and apes. (2012) (46)
- Antibody-mediated enhancement of viral disease. (2001) (45)
- Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung (2021) (43)
- Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes (2020) (41)
- mRNA-1273 Protects against SARS-CoV-2 Beta Infection in Nonhuman Primates (2021) (40)
- A New Approach for Monitoring Ebolavirus in Wild Great Apes (2014) (39)
- A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone (2020) (38)
- COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge (2021) (36)
- Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates (2021) (35)
- Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine. (2015) (35)
- Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates (2021) (32)
- SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity (2022) (31)
- Serologic Evidence of Ebolavirus Infection in a Population With No History of Outbreaks in the Democratic Republic of the Congo (2018) (31)
- β-Chemokine MDC and HIV-1 Infection (1998) (30)
- Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants (2021) (29)
- Dissociation of skeletal muscle for flow cytometric characterization of immune cells in macaques. (2015) (26)
- Chimpanzee Adenovirus Vector Ebola Vaccine--Preliminary Report. (2015) (25)
- Adenovirus Type 4 and 7 Vaccination or Adenovirus Type 4 Respiratory Infection Elicits Minimal Cross-Reactive Antibody Responses to Nonhuman Adenovirus Vaccine Vectors (2014) (24)
- Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. (2021) (22)
- Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes (2020) (21)
- Ebola Immunity: Gaining a Winning Position in Lightning Chess (2018) (21)
- Antibodies and resistance to natural HIV infection. (2000) (20)
- Ebola Virus Transmission Initiated by Systemic Ebola Virus Disease Relapse (2021) (19)
- High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident with mounting humoral immunity during acute COVID-19 (2021) (19)
- Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein. (2021) (15)
- mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron (2022) (14)
- Vaccine Generation of Protective Ebola Antibodies and Identification of Conserved B-Cell Signatures. (2018) (13)
- High-Throughput, Single-Copy Sequencing Reveals SARS-CoV-2 Spike Variants Coincident with Mounting Humoral Immunity during Acute COVID-19 (2021) (12)
- Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates (2021) (11)
- UK mutual fund performance (2006) (11)
- Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway (2021) (10)
- for Ebola virus infection in primates (2000) (9)
- Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates (2021) (9)
- Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron (2021) (8)
- Monoclonal antibodies to human transferrin: epitopic and phylogenetic analysis. (1988) (7)
- Rapid and Durable Protection Against Marburg Virus with a Single-Shot ChAd3-MARV GP Vaccine (2021) (6)
- An introduction to the Marburg virus vaccine consortium, MARVAC (2022) (5)
- Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels (2022) (4)
- Vaccine-Mediated Induction of an Ebolavirus Cross-Species Antibody Binding to Conserved Epitopes on the Glycoprotein Heptad Repeat 2/Membrane-Proximal External Junction. (2018) (4)
- A SARS-CoV-2 variant of concern triggers Fc effector function with increased cross-reactivity (2021) (3)
- CD8β Depletion Does Not Prevent Control of Viral Replication or Protection from Challenge in Macaques Chronically Infected with a Live Attenuated Simian Immunodeficiency Virus (2019) (3)
- Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. (2020) (3)
- Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron (2022) (3)
- Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA (2013) (2)
- Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial (2023) (2)
- A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates (2022) (2)
- A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challenge (2022) (2)
- A multispecific antibody confers pan-reactive SARS-CoV-2 neutralization and prevents immune escape (2022) (2)
- Extensive CD8β depletion does not prevent control of viral replication or protection from challenge in macaques chronically infected with a live attenuated simian immunodeficiency virus (2019) (1)
- Safety, Tolerability, Pharmacokinetics, and Immunogenicity of mAb114: A Phase 1 Trial of a Therapeutic Monoclonal Antibody Targeting Ebola Virus Glycoprotein (2019) (1)
- Ebola-GP DNA Prime rAd5-GP Boost: Influence of Prime Frequency and Prime/Boost Time Interval on the Immune Response in Non-human Primates (2021) (1)
- A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization (2022) (1)
- Overexpression of Ebola virus envelope GP1 protein. (2017) (1)
- A unique LPN to ADN bridge program. (1990) (1)
- Convergent epitope specificities, V gene usage and public clones elicited by primary exposure to SARS-CoV-2 variants. (2022) (1)
- Infiltration of dendritic cells and antigen uptake in the muscle after injection of HIV-1 Env gp120 in adjuvant (2012) (1)
- Monoclonal antibodies to human transferrin conservation of epitopes within primates (1985) (1)
- Title: Immune Correlates of Protection by mRNA-1273 Immunization against 1 SARS-CoV-2 Infection in Nonhuman Primates (2021) (0)
- Applications of high-throughput single B-cell sequencing to accelerate rational vaccine design (2016) (0)
- Loan Participations Q: Why Should Loan Participations be Part of Your Bank's Growth and Risk Management Strategy? (2015) (0)
- Molecular Dissection Of Human Antibody Responses Following Prefusion-Stabilized RSV F Vaccination (2020) (0)
- Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae (2013) (0)
- Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs (2022) (0)
- 20 – Ebola Vaccines (2018) (0)
- MULLEIN PITH IN EPILEPSY (1883) (0)
- 46 – Ebola vaccine (2013) (0)
- Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic (2017) (0)
- Probing theStructure oftheV2DomainofHuman Immunodeficiency Virus Type1Surface Glycoprotein gpl20 withaPanel ofEight Monoclonal Antibodies: Human ImmuneResponse totheVlandV2Domains (1993) (0)
- Development of a vaccine for the prevention of infections with filovirus in primates (2002) (0)
- IDENTIFICATION OF HUMAN T CELL EPITOPES IN THE EBOLAVIRUS GLYCOPROTEIN FOLLOWING VACCINATION WITH CHAD3 EBO Z GP AND MVA BN (2017) (0)
- Bridging Animal and Human Data in Pursuit of Vaccine Licensure (2022) (0)
- Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones (2022) (0)
- Safety and immunogenicity of the heterologous prime-boost ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN (R) FILO in healthy UK adults (2015) (0)
- Vaccine Development for Emerging Infections (2015) (0)
- gpl20 Glycoprotein on Subunit Association, Syncytium Formation, and Recognition by a Neutralizing Antibody (0)
- Drugs affecting cardiac rhythm (2012) (0)
- Safety and Immunogenicity of DNAVaccines Encoding Ebolavirus and Marburgvirus Wild- Type Glycoproteins in a Phase I Clinical Trial (2015) (0)
- Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones (2022) (0)
- Ebola Zaire DNA vaccine in comparison to its use in combination with DNA from (0)
- Immunologic Protection Against Ebola Infection: Where Are We? (2015) (0)
This paper list is powered by the following services:
Other Resources About Nancy Sullivan
What Schools Are Affiliated With Nancy Sullivan ?
Nancy Sullivan is affiliated with the following schools:
